Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,629.40 113.13 0.78%
TOPIX 1,180.43 7.06 0.60%
HANG SENG 22,760.24 64.23 0.28%

ThermoGenesis Announces New AXP(R) Customer in Portugal



ThermoGenesis Announces New AXP(R) Customer in Portugal

Crioestaminal is a Leading Cord Blood Bank in Europe

RANCHO CORDOVA, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- ThermoGenesis Corp.
(Nasdaq:KOOL), a leading supplier of enabling technologies for the processing,
storage and administration of cell therapies, today said equipment is on order
for its AXP^® AutoXpress^® System (AXP) from Crioestaminal, a leading cord
blood stem cell bank located in Cantanhede, Portugal.

The AXP System is a proprietary family of automated devices with companion
sterile blood processing disposables for harvesting cord blood stem cells in
closed systems.

"Crioestaminal is a pioneer and market leader in Portugal and a major European
cord blood bank. This is an important win for us as we will be replacing a
competitor's automated system at the facility, and it increases our footprint
in Europe. We expect to begin shipments from this new agreement in the current
month," said Matthew Plavan, Chief Executive Officer of ThermoGenesis.

"In addition, it demonstrates the value of our integrated distribution
strategy implemented last year, which is a customer-centric approach that
incorporates marketing, service and support for our cord blood products," he
noted.

"We are delighted to partner with ThermoGenesis and look forward to
implementing the AXP System. We have established a leading position in
Portugal's cord blood market and believe that the efficacy of the AXP will
enable us to further our market share growth," said Miguel Martí, Chief
Executive Officer of Crioestaminal.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and
manufacturing automated blood processing systems and disposable products that
enable the manufacture, preservation and delivery of cell and tissue therapy
products. These include:

  * The BioArchive^® System, an automated cryogenic device, used by cord blood
    stem cell banks in more than 30 countries for cryopreserving and archiving
    cord blood stem cell units for transplant.
     
  * AXP^® AutoXpress^® Platform (AXP), a proprietary family of automated
    devices that includes the AXP and the MXP^® MarrowXpress^® and companion
    sterile blood processing disposables for harvesting stem cells in closed
    systems. The AXP device is used for the processing of cord blood. The MXP
    is used for the preparation of cell concentrates, including stem cells
    from bone marrow aspirates in the laboratory setting.
     
  * The Res-Q^® 60 BMC/PRP (Res-Q), a point-of-care system designed for the
    preparation of cell concentrates, including stem cells, from bone marrow
    aspirates and whole blood for platelet rich plasma (PRP).

The ThermoGenesis Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=14120

   This press release contains forward-looking statements. These statements
  involve risks and uncertainties that could cause actual outcomes to differ
materially from those contemplated by the forward-looking statements. Several
 factors including timing of FDA and foreign regulatory approvals, changes in
customer forecasts, our failure to meet customers' purchase order and quality
requirements, supply shortages, production delays, changes in the markets for
 customers' products, introduction timing and acceptance of our new products
 scheduled for fiscal year 2013, and introduction of competitive products and
   other factors beyond our control could result in a materially different
revenue outcome and/or in our failure to achieve the revenue levels we expect
  for fiscal 2013. A more complete description of these and other risks that
    could cause actual events to differ from the outcomes predicted by our
 forward-looking statements is set forth under the caption "Risk Factors" in
 our annual report on Form 10-K and other reports we file with the Securities
  and Exchange Commission from time to time, and you should consider each of
        those factors when evaluating the forward-looking statements.

CONTACT:  ThermoGenesis Corp.
          Web site: http://www.thermogenesis.com
          Investor Relations
          +1-916-858-5107, or
          ir@thermogenesis.com

ThermoGenesis Corp. Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement